Primary Biliary Cholangitis: Personalizing Second-Line Therapies-R1

Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 12, 2024

Primary biliary cholangitis (PBC) is an enigmatic, autoimmune disease targeting the small intralobular bile ducts resulting in cholestasis and potentially progression to cirrhosis. Primarily affecting middle-aged women, diagnosis of PBC typically straightforward, with most patients presenting cholestatic liver tests highly specific antimitochondrial antibody. For decades, foundational treatment has been ursodeoxycholic acid, which delays but no impact on symptoms. Large cohort studies have established benefit maximizing reduction serum alkaline phosphatase levels acid need add second-line agents who do not achieve adequate response. Advances understanding physiology led development new that improve are predicted reduce risk progression. Obeticholic first therapy be approved for PBC, significantly improves biochemistries associated improved long-term clinical outcomes limited by its propensity induce pruritus. Elafibranor seladelpar peroxisome proliferator-activated receptor agonists recently use whereas bezafibrate fenofibrate available as off-label therapies. They also shown biochemical improvements among inadequate response may symptoms Herein, we review patient features consider when deciding whether a agent indicated truly personalized approach care.

Language: Английский

---

Obeticholic Acid vs Fibrates as Second-Line Therapy for Primary Biliary Cholangitis: Systematic Review and Meta-Analysis

Digestive Diseases and Sciences, Journal Year: 2025, Volume and Issue: unknown

Published: April 19, 2025

Language: Английский

---

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis: Time to change our targets?

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(1), P. 89 - 90

Published: May 21, 2024

LINKED CONTENT This article is linked to Gomez et al papers. To view these articles, visit https://doi.org/10.1111/apt.18004 and https://doi.org/10.1111/apt.18048

Language: Английский

---

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(1), P. 91 - 92

Published: May 21, 2024

LINKED CONTENT This article is linked to Gomez et al papers. To view these articles, visit https://doi.org/10.1111/apt.18004 and https://doi.org/10.1111/apt.18032

Language: Английский

---